Found 736 articles
Lexicon Pharmaceuticals, Inc., reported financial results for the three months ended March 31, 2022 and provided an update on key milestones.
Lexicon Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 5, 2022
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its first quarter 2022 financial results on Thursday, May 5, 2022 before the markets open.
4/11/2022It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look.
Lexicon Pharmaceuticals, Inc. announced that Jeffrey L. Wade, Lexicon’s president and chief financial officer, will present at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 8:45 a.m. ET.
The 71st annual American College of Cardiology's Scientific Session saw several wins over the weekend, led by some of the life sciences industries' largest companies.
Lexicon Pharmaceuticals, Inc. welcomes new guidelines for the management of heart failure issued jointly this past weekend by the American Heart Association, the American College of Cardiology and the Heart Failure Society of America.
Late-breaking data at ACC.22 with over 1 million patients demonstrates a major gap in guideline adherence resulting in higher mortality for patients with infected CIEDs
Royal Philips, a global leader in health technology, announced late-breaking results of a large-scale, real-world analysis of U.S. Centers for Medicare & Medicaid Services data on the rates of guideline adherence and associated mortality in patients with CIED infection.
Sotagliflozin Improved Outcomes in Patients With and Without Prior Cardiovascular Disease in New Analysis Presented at the American College of Cardiology's 71st Annual Scientific Session (ACC.22)
Lexicon Pharmaceuticals, Inc. announced results of a new analysis of data from the SCORED Phase 3 clinical trial of sotagliflozin that was presented at the American College of Cardiology’s 71st Annual Scientific Session.
Royal Philips, a global leader in health technology, is showcasing its integrated portfolio of diagnosis, guidance, and treatment solutions for atrial fibrillation at the 2022 European Heart Rhythm Association Annual Meeting.
New Analysis of Cardiovascular Endpoints in the SCORED Trial to Be Presented at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22)
Lexicon Pharmaceuticals, Inc. announced that an analysis of sotagliflozin data from the SCORED Phase 3 clinical trial will be presented as a late-breaker at the American College of Cardiology’s 71st Annual Scientific Session.
Lexicon Enters Into Loan Facility With Oxford Finance for Up to $150 Million to Support Planned Commercialization of Sotagliflozin
Lexicon Pharmaceuticals, Inc. announced it entered into a loan facility with Oxford Finance LLC that provides up to $150 million in borrowing capacity designed primarily to support commercial preparations and the potential launch of sotagliflozin in heart failure.
iCAD Highlights Breast Health AI Platform at the 2022 Healthcare Information and Management Systems Society (HIMSS) MeetingWorld-leading breast cancer AI solutions featured for demonstration in iCAD booth
iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will be showcasing its portfolio of Breast AI solutions, including ProFound AI® for Digital Breast Tomosynthesis (DBT) in the iCAD booth (#4000) at the 2022 Healthcare Information and Management Systems Society (HIMSS) Global Health Conference & Exhibition.
Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Clinical Update
Lexicon Pharmaceuticals, Inc. reported financial results for the three months and full-year ended December 31, 2021 and provided an update on key milestones.
Lexicon Voluntarily Withdraws Sotagliflozin New Drug Application and Plans Prompt Resubmission Targeted Early Q2 2022
Lexicon Pharmaceuticals, Inc. announced the voluntary withdrawal and planned near-term resubmission of the company’s New Drug Application for sotagliflozin to correct a technical issue with the submission recently identified by the company.
Lexicon Pharmaceuticals to Host Fourth Quarter 2021 Financial Results Conference Call and Webcast on February 28, 2022
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter 2021 financial results on Monday, February 28, 2022 before the markets open. Management will conduct a conference call and live webcast at 8:00 a.m. ET (7:00 a.m. CT) that day to discuss its financial and operating results and to provide a general business update.
Biosion, Inc., a global clinical stage biotechnology company, announced the appointment of Joel Edwards as chief business officer.
BTR Raises $15 Million in Series A Round to Transform the Validation Process for Life Sciences Companies
BTR (Boston Technology Research), a regulatory technology company serving healthcare, life sciences and SaMD, today announced that is has raised $15 million in a Series A round led by New York-based global venture capital and private equity firm Insight Partners.
Lexicon Pharmaceuticals Outlines Major Potential Value Drivers for 2022 at 40th Annual J.P. Morgan Healthcare Conference
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) is outlining major potential value drivers for 2022 at this morning’s presentation at the 40th Annual J.P. Morgan Healthcare Conference.
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicon’s chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 10:30 a.m. ET.
Lexicon Submits New Drug Application for Sotagliflozin for the Treatment of Heart Failure in Adults With Type 2 Diabetes
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval for the marketing and sale of sotagliflozin.